Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Convertible Debt - Related Party (Tables)

Convertible Debt - Related Party (Tables)

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Schedule of convertible debt

		As of September 30, 2019				As of December 31, 2018
Total principal value		$	6,000,000			$	2,000,000
Unamortized debt discount			(2,652,112	)			(587,617	)
Unamortized debt issuance costs			(51,639	)			(51,423	)
Carrying value of total convertible debt — related party		$	3,296,249			$	1,360,960
Less, noncurrent portion			(3,296,249	)			(1,360,960	)
Current convertible debt — related party		$	—			$	—

Schedule of interest expense

		Three Months Ended September 30,								Nine Months Ended September 30,
		2019				2018				2019				2018
Interest expense – stated rate		$	107,334			$	—			$	272,611			$	3,100
Non-cash interest expense:
Amortization of debt discount			190,886				—				429,355				34,608
Amortization of transaction costs			3,327				—				9,609				—
		$	301,547			$	—			$	711,575			$	37,708